Share Twitter LinkedIn Facebook Email Prof Wee Joo Chng, MD discusses the importance of Minimal Residual Disease (MRD) testing in Multiple Myeloma Advertisement Single Below Content Advertisement Single Below Content Advertisement Single Below Content
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read